Based on data from The Cancer GenomeAtlas GBM database, more than 50% of GBM patients exhibit either overexpressionor mutations in epidermal growth factor receptor (EGFR).90 The most frequent mutation, EGFR variant III(EGFRvIII), is present in one-fourth of GBMs with EGFR amplificationbut is absent in normal tissues.91 Additionally,this receptor variant has been revealed to be upregulated in GSCs.92 Therefore, Mao and colleagues constructed PTX-loadedPEG–PLA micelles modified with D-AE, a selective ligand toboth EGFR and EGFRvIII. The gene discussed is EGFR; the disease is glioblastoma.